http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ryu, Dal-Sung,Hong, Chang-Ki,Sim, Yoo-Sik,Kim, Chang-Hyun,Jung, Jin-Young,Joo, Jin-Yang The Korean Neurosurgical Society 2010 Journal of Korean neurosurgical society Vol.48 No.4
Objective : The aim of this study was to analyze the correlation between thromboembolic complications and anti platelet drugs before and after neurointervention. Methods : Blood samples and radiographic data of patients who received a neurointervention (coil embolization, stent placement or both) were collected prospectively. Rapid platelet function assay-aspirin (RPFA-ASA) was used to calculate aspirin resistance in aspirin reaction units (ARU). For clopidogrel resistance, a P2Y12 assay was used to analyze the percentage of platelet inhibition. ARU > 550 and platelet inhibition < 40% were defined as aspirin and clopidogrel resistance, respectively. Results : Both aspirin and clopidogrel oral pills were administered in fifty-three patients before and after neurointerventional procedures. The mean resistance values of all patients were 484 ARU and < 39%. Ten (17.0%) of 53 patients showed resistance to aspirin with an average of 597 ARU, and 33 (62.3%) of 53 patients showed resistance to clopidogrel with an average of < 26%. Ten patients demonstrated resistance to both drugs, 5 of which suffered a thromboembolic complication after neurointervention (mean values : 640 ARU and platelet inhibition < 23%). Diabetic patients and patients with hypercholesterolemia displayed mean aspirin resistances of 513.7 and 501.8 ARU, and mean clopidogrel resistances of < 33.8% and < 40.7%, respectively. Conclusion : Identifying individuals with poor platelet inhibition using standard regimens is of great clinical importance and may help prevent cerebral ischemic events in the future. Neurointerventional research should focus on ideal doses, timing, choices, safety, and reliable measurements of anti platelet drug therapy, as well as confirming the clinical relevance of aggregometry in cerebrovascular patients.
Ryu, Chang Hwan,Ryu, Junsun,Ryu, Youn Mi,Lee, You Jin,Lee, Eun-Kyung,Kim, Seok-Ki,Kim, Tae-Sung,Kim, Tae Hyun,Lee, Chang Yoon,Park, Seog Yun,Chung, Ki Wook,Jung, Yuh-S. Society of Nuclear Medicine 2015 The Journal of nuclear medicine Vol.56 No.10
<P>The purpose of this study was to evaluate the impact of radioactive iodine therapy (RIT) on vocal function during the early follow-up period after total thyroidectomy (TT) using perceptive and objective measurements, questionnaires regarding subjective symptoms, and data on vocal function in a prospectively enrolled and serially followed thyroid cancer cohort. <B>Methods:</B> Of 212 patients who underwent TT and were screened between January and December 2010 at our hospital, 160 were included in the final analysis. Patients with the following histories were excluded: lateral neck dissection, organic vocal fold disease, external radiotherapy, and voice evaluation during thyroxine withdrawal. Patients were stratified into 3 groups: TT, TT with low-dose RIT (1.1–2.2 GBq), and TT with high-dose RIT (≥3.7 GBq). Voice evaluations were performed before surgery and at 1, 6, and 12 mo after TT. <B>Results:</B> Vocal characteristics were altered after TT, including changes on the grade, roughness, and strain scale; increased amplitude perturbation; decreased fundamental frequency; narrowed pitch range; and global disturbances in subjective functional parameters on the voice handicap index. However, the degree of vocal changes among the 3 groups did not significantly differ within the 1-y postoperative follow-up period. According to the results of subgroup analyses of patients who demonstrated good voice outcomes after TT, there were no significant functional differences among the 3 groups. <B>Conclusion:</B> RIT at any dose does not affect vocal function within 1 y of TT.</P>
HYUN, HWANG-BO,LEE, WON SUP,GO, SE-IL,NAGAPPAN, ARULKUMAR,PARK, CHEOL,HAN, MIN HO,HONG, SU HYUN,KIM, GONSUP,KIM, GI YOUNG,CHEONG, JAEHUN,RYU, CHUNG HO,SHIN, SUNG CHUL,CHOI, YUNG HYUN Spandidos Publications 2015 International journal of oncology Vol.46 No.6
<P>It is evident based on literature that flavonoids from fruit can safely modulate cancer cell biology and induce apoptosis. Therefore, we investigated the anticancer activity of morin, a flavonoid which is plentiful in twigs of mulberry focusing on apoptosis, and its mechanisms. Morin upregulated the Fas receptor, and activates caspase-8, -9 and -3 in HCT-116 cells. Morin also activates Bid, and induced the loss of mitochondrial membrane potential (MMP, ?ψm) with Bax protein activation and cytochrome c release. In addition, morin induced ROS generation which was not blocked by N-acetylcysteine. Morin also suppressed Bcl-2 and cIAP-1, anti-apoptotic proteins, which may contribute to augmentation of morin-triggered apoptosis. As an upstream signaling pathway, suppressed Akt activity by morin was associated to apoptosis. This study suggests that morin induces caspase-dependent apoptosis through extrinsic pathway by upregulating Fas receptor as well as through the intrinsic pathway by modulating Bcl-2 and IAP family members, and ROS generation, and that Akt is the critical upstream signaling that regulates the apoptotic effect of morin in human colon cancer HCT-116 cells.</P>
Cause of mortality in patients with corticosteroid-dependent asthma
( Hyun Lee ),( Jiin Ryu ),( Eunwoo Nam ),( Min Ju Jo ),( Sung Jun Chung ),( Yoomi Yeo ),( Dong Won Park ),( Tai Sun Park ),( Ji-yong Moon ),( Tae-hyung Kim ),( Jang Won Sohn ),( Sang-heon Kim ),( Ho J 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Patients with corticosteroid (CS)-dependent asthma have higher mortality than those with CS-independent asthma. However, the common causes of mortality and cause-specific mortality risk in this population have not been well elucidated. Methods: We performed a population-based 1:1 matched cohort of patients with CS-dependent asthma (CSuse> 6 months during baseline period) (n=8,334) and CS-independent asthma (CS-use<6 months during baseline period) (n=8,223) using the Korean National Health Insurance Services (NHIS) data.We determined hazards ratios (HRs) and 95% confidence intervals (CIs) for each cause of mortality. We also performed a cause-specific and subdistribution proportional hazards regression model to account for competing risks caused by mortality from other causes. Results: The overall mortality was 5,191/100,000 person-years during a median of 9.5 years (interquartile range, 5.5-9.9 years) of follow-up. All-cause mortality was higher in the CS-dependent cohort than in the CS-independent cohort (6,760/100,000 versus 3,833/100,000 person-years, p<0.001). The common causes of mortality in patients with CS-dependent asthma were respiratory diseases (46.3%), cardiovascular diseases (17.7%), malignant neoplasms (14.2%), injury, poisoning, and external causes (4.8%), and endocrine diseases (3.5%). Compared with patients in the CS-dependent cohort, those in the CS-dependent cohort were more likely to die due to the following causes; respiratory diseases (HR=3.12, 95% CI = 2.85-3.42), cardiovascular diseases (HR=1.28, 95% CI=1.15-1.43), malignant neoplasms (HR=1.14, 95% CI=1.01-1.28), injury, poisoning, and external causes (HR=1.40, 95% CI=1.13-1.74), and endocrine diseases (HR=1.71, 95% CI=1.30-2.23). When considering competing risks caused by mortality due to other diseases, mortality risks were especially significant for chronic respiratory diseases (subdistribution HR=2.96, 95% CI=2.70-3.24) and endocrine diseases (subdistribution HR=1.49, 95% CI=1.14-1.95). Conclusions: The common causes of mortality in CS-dependent asthma were respiratory diseases, cardiovascular diseases, malignancy, injury, poisoning, and external causes, and endocrine diseases. Compared with CS-independent asthma patients, CS-dependent asthma patients had higher disease-specific mortality risk for respiratory diseases and endocrine diseases.
Comorbid bronchiectasis increases the mortality of corticosteroid-dependent asthma
( Hyun Lee ),( Jiin Ryu ),( Eunwoo Nam ),( Min Ju Jo ),( Sung Jun Chung ),( Yoomi Yeo ),( Dong Won Park ),( Tai Sun Park ),( Ji-yong Moon ),( Tae-hyung Kim ),( Jang Won Sohn ),( Sang-heon Kim ),( Ho J 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Bronchiectasis is a common comorbid condition in patients with severe asthma, of whom up to two-thirds are corticosteroid (CS)-dependent. However, there are uncertainty whether comorbid bronchiectasis is associated with long-term mortality in patients with CS-dependent asthma. Methods: Using data from the Korean National Health Insurance Services (NHIS), a population-based 1:1 matched cohort of patients with CS-dependent asthma (CS use > 6 months during baseline period) (n = 8,334) and CS-independent asthma (CS use < 6 months during baseline period) (n = 8,223) was performed. Each group was further subclassified according to the presence or absence of bronchiectasis. Hazard ratios (HRs) with 95% confidence intervals (CIs) for all-cause mortality among CS-dependent asthma patients with bronchiectasis, CS-dependent asthma patients without bronchiectasis, and CS-independent asthma patients with bronchiectasis relative to CS-independent asthma patients without bronchiectasis were evaluated. Results: In both CS-dependent and CS-independent cohort, those with bronchiectasis were more likely to be older (p = 0.020), receive medical aid as a type of insurance (p < 0.001), and have higher Charlson comorbidities index (p < 0.001). Compared with patients without bronchiectasis, those with bronchiectasis were more likely to have metabolic diseases (p < 0.001), pulmonary infectious diseases (p < 0.001), and cardiovascular diseases (p = 0.041). There was no significant increased HR for mortality in CS-dependent asthma patients with bronchiectasis relative to CS-dependent asthma patients without bronchiectasis (HR = 1.18, 95% CI = 0.92-1.50). However, CS-dependent asthma patients with bronchiectasis and those without bronchiectasis were 2.18 (95% CI = 2.041-2.33) and 2.32 (95% CI = 1.92-2.81) times higher mortality compared with CS-independent asthma patients without bronchiectasis, respectively. Conclusion: Comorbid bronchiectasis is associated with increased mortality risk in patients with CS-dependent asthma.
Ryu, Jae Yong,Kim, Hyun Uk,Lee, Sang Yup The Royal Society of Chemistry 2015 Molecular bioSystems Vol.11 No.10
<P>Alternative splicing is a process observed in gene expression that results in a multi-exon gene to produce multiple mRNA variants which might have different functions and activities. Although physiologically important, many aspects of genes with different number of transcript variants (or splice variants) still remain to be characterized. In this study, we provide bioinformatic evidence that genes with a greater number of transcript variants are more likely to play functionally important roles in cells, compared with those having fewer transcript variants. Among 21 983 human genes, 3728 genes were found to have a single transcript, and the remaining genes had 2 to 77 transcript variants. The genes with more transcript variants exhibited greater frequencies of acting as housekeeping and essential genes rather than tissue-selective and non-essential genes. They were found to be more conserved among 64 vertebrate species as orthologs, subjected to regulations by transcription factors and microRNAs, and showed hub node-like properties in the human protein–protein interaction network. These findings were also confirmed by metabolic simulations of 60 cancer metabolic models. All these results indicate that genes with a greater number of transcript variants play biologically more fundamental roles.</P> <P>Graphic Abstract</P><P>Human genes with a greater number of transcript variants are more likely to play functionally important roles such as cellular maintenance and survival. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c5mb00322a'> </P>